Dow Chemical has agreed for Dowpharma, Dow's pharmaceutical
manufacturing services business unit, to supply select, proprietary
oligonucleotides to Montreal, Canada-based Topigen Pharmaceuticals
for use in its pharmaceutical...
There has been 'unprecedented development' in terms of the
Community's research policy in the last year claims the European
Commission's 2002 annual report on technological research and
development (RTD) in 2001.
A collaboration between Cenix BioScience of Germany and the USA's
Ambion has been formed to co-develop and market the first
commercially-available, human genome-wide library of small
interfering RNA sequences. RNA interference...
Biotechnology company Biogen this week celebrated its 25th
anniversary by breaking the ground on a large-scale manufacturing
facility in Hillerød, Denmark, marking the company's first
development phase for the region and a greater...
Pharmaceutical researchers used to begin their evaluation of drug
leads by looking at affinity and potency, but a
genomics/informatics-based research culture is now growing which is
starting to impinge on this classical mode, says...
UK contract pharmaceutical manufacturer and distributor Intercare
Group has reported 2002 turnover of £275.1 million (€406m), an
increase of 27 per cent year-on-year, and pretax profits of £24.6
million, up 15 per cent. The results...
Data published by the Danish Association of the Pharmaceutical
Industry (LIF) reveals a boom in pharmaceutical exports in 2002.
Sales totalled DK30.3 billion (€4.3 billion), an increase of
approximately DK2 billion (€268 million)...
Scientists in Australia report this week that they have developed a
powerful software modelling tool, MolSAR, which could have the
potential to reduce drug development costs by up to €28 million per
Dharmacon, a US supplier of RNA and RNA-interference research
products, announced today it has launched Cell Cycle siARRAY, a
collection of ready-to-use siRNA duplexes designed to knock down
112 genes involved in cell cycle regulation.
Venture capital investments in biotechnology and medical device
companies combined to total $4.7 billion (€4.4bn) in 2002, or 22
per cent of all investing, representing the highest proportion in
seven years, according to the MoneyTree...
Ireland's Elan Corp has inked a deal with Ingenium Pharmaceuticals
of Germany that will see the companies apply Ingenium's functional
genomics technologies to the discovery and development of novel
therapeutics for pain...